These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3027336)

  • 1. Bimorphinans as highly selective, potent kappa opioid receptor antagonists.
    Portoghese AS; Lipkowski AW; Takemori AE
    J Med Chem; 1987 Feb; 30(2):238-9. PubMed ID: 3027336
    [No Abstract]   [Full Text] [Related]  

  • 2. (-)-N,N'-but-2-ene-1,4-diylbimorphinans.
    Schmidhammer H; Smith CF; Dalkner E; Erlach D; Heuberger M; Rollinger JM
    Pharmazie; 1991 Feb; 46(2):101-2. PubMed ID: 1649476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
    Ananthan S; Kezar HS; Saini SK; Khare NK; Davis P; Dersch CM; Porreca F; Rothman RB
    Bioorg Med Chem Lett; 2003 Feb; 13(3):529-32. PubMed ID: 12565965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel series of potent and selective agonists at the opioid kappa-receptor.
    Costello GF; Main BG; Barlow JJ; Carroll JA; Shaw JS
    Eur J Pharmacol; 1988 Jul; 151(3):475-8. PubMed ID: 2850924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.
    Portoghese PS; Larson DL; Sayre LM; Fries DS; Takemori AE
    J Med Chem; 1980 Mar; 23(3):233-4. PubMed ID: 6245210
    [No Abstract]   [Full Text] [Related]  

  • 7. Agonist and antagonist opioid activity of axial and equatorial conformations of S-methyl- and S-allyl-morphinans.
    Lemaire S; Belleau B; Jolicoeur FB
    Eur J Pharmacol; 1994 Jun; 258(1-2):111-8. PubMed ID: 7925589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An opioid agonist with preference for kappa-opioid receptors: (-)-N-cyclopropylmethylmorphinan-6-one.
    Schmidhammer H; Trenker E; Burkard WP; Eggstein-Aeppli L; Hefti F; Holck MI
    Arch Pharm (Weinheim); 1990 Jan; 323(1):27-9. PubMed ID: 1970719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probes for narcotic receptor-mediated phenomena. 20. Alteration of opioid receptor subtype selectivity of the 5-(3-hydroxyphenyl)morphans by application of the message-address concept: preparation of delta-opioid receptor ligands.
    Bertha CM; Flippen-Anderson JL; Rothman RB; Porreca F; Davis P; Xu H; Becketts K; Cha XY; Rice KC
    J Med Chem; 1995 Apr; 38(9):1523-37. PubMed ID: 7739011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.
    Traynor JR; Corbett AD; Kosterlitz HW
    Eur J Pharmacol; 1987 May; 137(1):85-9. PubMed ID: 3038579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
    Spetea M; Greiner E; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2005 Jul; 48(15):5052-5. PubMed ID: 16033285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
    Lattanzi R; Spetea M; Schüllner F; Rief SB; Krassnig R; Negri L; Schmidhammer H
    J Med Chem; 2005 May; 48(9):3372-8. PubMed ID: 15857143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist.
    Portoghese PS; Sultana M; Takemori AE
    Eur J Pharmacol; 1988 Jan; 146(1):185-6. PubMed ID: 2832195
    [No Abstract]   [Full Text] [Related]  

  • 14. Design and synthesis of highly potent and selective cyclic dynorphin A analogues.
    Kawasaki AM; Knapp RJ; Kramer TH; Wire WS; Vasquez OS; Yamamura HI; Burks TF; Hruby VJ
    J Med Chem; 1990 Jul; 33(7):1874-9. PubMed ID: 1972964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine.
    Portoghese PS; Garzon-Aburbeh A; Nagase H; Lin CE; Takemori AE
    J Med Chem; 1991 Apr; 34(4):1292-6. PubMed ID: 1849995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyprodime analogues: synthesis and pharmacological evaluation.
    Schmidhammer H; Smith CF; Erlach D; Koch M; Krassnig R; Schwetz W; Wechner C
    Prog Clin Biol Res; 1990; 328():37-40. PubMed ID: 2154795
    [No Abstract]   [Full Text] [Related]  

  • 17. Opioid activity of a benzomorphan lacking an oxygen atom.
    Goldstein A; Naidu A
    Biochem Pharmacol; 1978 Apr; 27(7):1033-6. PubMed ID: 207286
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
    Cox BM; Chavkin C
    Mol Pharmacol; 1983 Jan; 23(1):36-43. PubMed ID: 6135144
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of the kappa-opioid activity of a series of 6,7-benzomorphans in the rabbit vas deferens.
    Verlinde C; De Ranter C
    Eur J Pharmacol; 1988 Aug; 153(1):83-7. PubMed ID: 2850928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of opioid receptors on gastric muscle cells by selective receptor protection.
    Grider JR; Makhlouf GM
    Am J Physiol; 1991 Jan; 260(1 Pt 1):G103-7. PubMed ID: 1670978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.